A Solana-based token tied to Anthropic's pre-IPO valuation saw $274,000 in trading volume within 24 hours on October 19, despite Anthropic having no public stock ticker. Issued by PreStocks and listed on CoinGecko, the token was priced around $985 with a market cap near $7.56 million. This token represents a market for Anthropic's valuation but is distinct from the company's pre-IPO perpetual contracts, which have seen $643 million in trading volume across multiple venues. The token provides a way for investors to engage with Anthropic's value before any public offering.
The Anthropic-linked Solana token saw notable trading interest recently. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Oct 19, 2026 15:02 WIB: out of 50 major cryptocurrencies, 41 rose and 8 fell. Cosmos (ATOM) rose 2.75% to Rp31.413 with a typical hold time of 61 days and 77% buy orders. Polkadot (DOT) increased 2.62% to Rp20.273 with 89% buy orders. Basic Attention Token (BAT) gained 2.53% to Rp3.300 with 93% buy orders.
Jyske Bank has repurchased shares valued at approximately DKK 2.15 billion as part of its ongoing share buyback program running from February 2026 to January 2027. The bank has acquired a total of 2,235,959 treasury shares, representing 3.84% of its ...
Jyske Bank is conducting a share buyback program from February 5, 2026, to January 29, 2027, with a maximum value of DKK 3 billion. As of mid-October 2026, the bank has repurchased shares worth approximately DKK 2.15 billion at an average price of DK...
Oculis Holding AG has completed patient randomization in its PREDICT-1 clinical trial testing Licaminlimab, a precision medicine targeting TNFR1-mediated dry eye disease (DED). Two-thirds of the 176 enrolled patients carry a genetic variant linked to...
Ekalia, a joint venture between IBA and Framatome, has signed a collaboration agreement with Telix Pharmaceuticals to accelerate the production of astatine-211 in the United States. Astatine-211 is a promising alpha-emitting radioisotope used in targ...
At ESMO 2026, Roche presented key Phase III trial results showcasing significant advances in cancer treatment. Divarasib demonstrated superior efficacy over first-generation KRAS G12C inhibitors in advanced lung cancer, potentially setting a new stan...
